Understanding Ketamine Safety: Risks, Side Effects, and Best Practices

The Safety Landscape of Ketamine

Ketamine occupies a unique position in the safety conversation. It has been used continuously in clinical medicine since its FDA approval in 1970 — more than half a century of human use across anesthesia, emergency medicine, pediatrics, pain management, and psychiatry. The World Health Organization lists it as an Essential Medicine, reflecting a safety and efficacy profile that is well-established for its traditional applications.

However, the newer psychiatric application of ketamine — repeated sub-anesthetic dosing over months or years — is a fundamentally different use case than the single-dose anesthetic or emergency applications that built ketamine's original safety record. Understanding the distinction between what is known from decades of use and what remains under investigation is critical for patients, providers, and the field as a whole.

This guide provides a comprehensive, evidence-based overview of ketamine's safety profile across all relevant dimensions.

Acute Side Effects: What Happens During Treatment

Dissociative Effects

Dissociation is the most characteristic acute effect of ketamine at sub-anesthetic doses. It is not technically a "side effect" in the traditional sense — it is a core pharmacological property of the drug. Patients may experience:

• A sense of floating or detachment from the body
• Altered perception of time (time may seem to slow down or speed up)
• Dreamlike or surreal visual experiences
• Heightened sensitivity to music and sound
• A feeling of distance from usual thought patterns
• In some cases, profound experiences described as spiritual or mystical

The intensity of dissociation is dose-dependent and varies significantly between individuals. At the standard IV dose of 0.5 mg/kg over 40 minutes, most patients experience mild to moderate dissociative effects. These effects peak during the infusion (or shortly after administration for other routes) and typically resolve within 60-90 minutes.

For most patients, dissociation is tolerable and sometimes therapeutically valuable. Some patients find it uncomfortable, particularly during initial sessions. Preparation, appropriate setting, and supportive clinical staff can significantly improve the experience.

Cardiovascular Effects

Ketamine produces sympathomimetic effects — it temporarily increases sympathetic nervous system activity, resulting in:

• Blood pressure elevation — Systolic blood pressure typically increases by 15-25 mmHg during treatment, with larger increases possible in some individuals
• Heart rate increase — Heart rate may increase by 10-20 beats per minute
• Cardiac output increase — Overall cardiac output increases, which is one reason ketamine is favored in emergency settings for hemodynamically unstable patients

These cardiovascular changes are temporary and typically return to baseline within 30-60 minutes after treatment ends. In healthy individuals, they are clinically insignificant. However, they require careful consideration in patients with cardiovascular risk factors.

Monitoring Protocol

Standard cardiovascular monitoring during ketamine therapy includes:

• Blood pressure measurement before, during (at regular intervals), and after treatment
• Heart rate monitoring
• Pulse oximetry (oxygen saturation)
• Most clinics have predetermined thresholds for temporarily pausing or discontinuing treatment if blood pressure exceeds safe limits

Nausea and Vomiting

Nausea is reported by approximately 15-30% of patients receiving sub-anesthetic ketamine. Vomiting is less common, occurring in approximately 5-10% of patients. Risk factors include:

• Higher doses
• Faster infusion rates
• Female sex
• History of motion sickness
• Oral or sublingual administration (due to the taste)

Nausea can be effectively managed with:

• Pre-treatment with ondansetron (Zofran) or other antiemetics
• Ginger supplements or ginger ale
• Slower infusion rates
• Fasting for 4-6 hours before treatment (clear liquids are typically permitted)

Dizziness and Coordination

Patients commonly experience dizziness, lightheadedness, and impaired coordination during and shortly after ketamine treatment. This is an expected pharmacological effect and is the primary reason patients are instructed not to drive or operate machinery for at least 12-24 hours after treatment.

Walking assistance should be available during the recovery period. Some clinics have patients remain seated or reclined until they feel steady on their feet and pass a simple coordination assessment.

Visual and Perceptual Changes

Visual disturbances are common and may include:

• Blurred or double vision
• Enhanced color perception
• Mild visual distortions or patterns
• Altered depth perception

These effects are temporary and dose-related. They typically resolve within 1-2 hours and do not indicate any underlying visual or neurological problem.

Headache

Approximately 15-20% of patients report headache following ketamine treatment. These headaches are typically mild, respond to standard over-the-counter analgesics, and do not recur with subsequent treatments in most cases.

Psychological Side Effects

A small percentage of patients may experience:

• Anxiety or panic during the dissociative state, particularly if unprepared
• Emotional release — crying, laughter, or intense emotional experiences
• Confusion or disorientation during the acute effects
• Vivid dreams or nightmares in the hours following treatment
• Transient depersonalization or derealization that occasionally persists beyond the acute treatment period

These effects are generally self-limiting. Proper preparation, a comfortable setting, and the presence of supportive clinical staff significantly reduce the frequency and intensity of adverse psychological experiences.

Contraindications: Who Should Not Receive Ketamine

Absolute Contraindications

Certain conditions make ketamine therapy inappropriate due to unacceptable risk:

Uncontrolled hypertension. Because ketamine raises blood pressure, it should not be used in patients with uncontrolled high blood pressure. Blood pressure should be adequately managed before beginning ketamine therapy.

Active psychotic disorders. Patients with active schizophrenia, schizoaffective disorder, or other psychotic disorders should not receive ketamine. The drug's effects on glutamate and its psychotomimetic properties at higher doses could theoretically worsen psychotic symptoms. A history of psychosis does not necessarily preclude treatment if the patient is currently stable and under psychiatric care, though this requires careful clinical judgment.

Known hypersensitivity. Patients with a known allergy or severe adverse reaction to ketamine should not receive it.

Pregnancy. Ketamine is not recommended during pregnancy due to insufficient safety data and potential concerns about effects on fetal development. Animal studies at high doses have raised neurodevelopmental concerns, though the relevance to human sub-anesthetic use is unclear.

Intracranial hypertension. Ketamine was historically considered contraindicated in raised intracranial pressure. While more recent evidence suggests this concern may be overstated, caution remains appropriate.

Relative Contraindications and Cautions

These conditions do not necessarily preclude treatment but require careful consideration, additional monitoring, or modified protocols:

Cardiovascular disease. Patients with unstable angina, recent myocardial infarction, heart failure, aortic aneurysm, or arrhythmias need thorough cardiovascular evaluation and may require cardiology clearance before treatment. Modified protocols with lower doses or slower infusion rates may be appropriate.

Liver disease. Ketamine is metabolized primarily by the liver. Patients with significant hepatic impairment may metabolize the drug more slowly, leading to prolonged effects and potentially higher blood levels. Dose adjustments and monitoring may be needed.

History of substance use disorders. Ketamine has abuse potential, and patients with active or recent substance use disorders (particularly involving ketamine, PCP, or other dissociatives) require careful risk-benefit assessment. A history of substance use disorder is not an absolute contraindication, but it necessitates additional safeguards, closer monitoring, and clear prescribing boundaries.

Bladder conditions. Patients with pre-existing interstitial cystitis, overactive bladder, or other lower urinary tract symptoms should be monitored carefully, as ketamine can affect bladder function.

Thyroid disorders. Uncontrolled hyperthyroidism can amplify ketamine's cardiovascular effects and should be managed before treatment.

Glaucoma. Ketamine may temporarily increase intraocular pressure, requiring caution in patients with glaucoma.

Drug Interactions

Medications That May Attenuate Ketamine's Effects

Benzodiazepines. Preclinical and some clinical evidence suggests that benzodiazepines (lorazepam, diazepam, clonazepam, alprazolam) may reduce ketamine's antidepressant efficacy by dampening the glutamate surge and AMPA receptor activation that are central to its mechanism. Some clinicians recommend tapering benzodiazepines before initiating ketamine therapy, though this must be balanced against the risks of benzodiazepine withdrawal.

Lamotrigine. This mood stabilizer, which modulates glutamate release, has shown mixed evidence regarding potential interaction with ketamine. Some studies suggest it may reduce ketamine's dissociative effects without affecting antidepressant efficacy, while others suggest possible attenuation.

Medications That May Amplify Effects

CNS depressants. Opioids, alcohol, sedative-hypnotics, and other central nervous system depressants can potentiate ketamine's sedative and respiratory depressant effects. Patients should disclose all CNS-active substances to their provider.

MAO inhibitors. Monoamine oxidase inhibitors may theoretically interact with ketamine's sympathomimetic effects, though clinical data on this interaction are limited. Caution is warranted.

Stimulants. The combination of ketamine's sympathomimetic properties with stimulant medications may increase cardiovascular strain. Additional blood pressure monitoring may be appropriate.

Medications That Are Generally Safe to Combine

Ketamine can generally be used alongside most common psychiatric medications, including SSRIs, SNRIs, bupropion, mirtazapine, lithium, and most atypical antipsychotics. However, patients should provide a complete medication list to their prescribing clinician, and any changes to medications should be coordinated.

Long-Term Safety Considerations

Bladder Health

The most well-known long-term concern with ketamine use is urological damage, particularly ketamine-induced cystitis. This condition has been extensively documented in chronic recreational users and is characterized by:

• Reduced bladder capacity
• Urinary frequency and urgency
• Pelvic pain
• In severe cases, ulceration and fibrosis of the bladder wall

However, a critical distinction must be drawn between recreational and therapeutic use:

• Recreational abuse associated with bladder damage typically involves daily or near-daily use of high doses (1-5 grams per day or more) over months to years
• Therapeutic use involves much lower doses (typically 0.5 mg/kg per session), much less frequently (weekly to monthly), with total cumulative exposure that is orders of magnitude lower than that associated with bladder damage

Current evidence does not suggest that ketamine therapy at standard clinical doses and frequencies causes significant bladder pathology. Multiple studies of patients receiving repeated therapeutic ketamine have not found clinically significant urological adverse effects. Nevertheless, monitoring for urinary symptoms (frequency, urgency, pain, blood in urine) is standard practice, and any emerging symptoms should prompt clinical evaluation.

Cognitive Function

The potential for cognitive effects is another area of careful investigation:

Acute cognitive effects — During and shortly after treatment, ketamine impairs attention, working memory, and executive function. These effects are dose-dependent and fully reversible, typically resolving within 2-4 hours.

Chronic recreational use — Long-term heavy recreational ketamine users have shown deficits in episodic memory, semantic memory, and executive function in some studies. These deficits appear to be dose-dependent and may be partially reversible with cessation.

Therapeutic use — Studies of patients receiving repeated therapeutic ketamine treatments (at standard clinical doses and frequencies) have generally not found clinically significant long-term cognitive impairment. Some studies have actually reported improvements in cognitive function, likely related to the treatment of depression (which itself causes cognitive impairment).

A comprehensive systematic review should be discussed with the treating clinician, who can weigh the cognitive risks against the cognitive burden of untreated depression.

Dependence and Addiction Potential

Ketamine is a Schedule III controlled substance, indicating moderate potential for dependence. Understanding this risk requires nuance:

Pharmacological mechanisms. Ketamine's subjective effects (euphoria, dissociation, altered perception) activate reward pathways in the brain, which can theoretically lead to psychological dependence in some individuals. Physical dependence (with a defined withdrawal syndrome) can develop with chronic daily use at high doses but has not been reported at therapeutic doses and frequencies.

Clinical evidence. In the published literature on ketamine therapy for psychiatric conditions, reports of patients developing dependence on their therapeutic ketamine are rare. The controlled clinical setting, specific dosing protocols, and medical oversight inherent in therapeutic use are substantial protective factors.

Risk factors. Patients with a personal or family history of substance use disorders, particularly involving dissociatives, stimulants, or opioids, may be at higher risk. These patients warrant additional screening, closer monitoring, and clear prescribing boundaries. Use of a "ketamine contract" or treatment agreement is common practice.

Safeguards in clinical practice:

• Prescribing controlled amounts (no large supplies)
• Regular clinical assessments for signs of escalating use or psychological dependence
• Structured treatment protocols with defined endpoints
• Monitoring for requests for dose increases beyond clinical need
• Avoiding prescribing to patients in active substance abuse without appropriate addiction medicine involvement

Hepatic Effects

Ketamine is metabolized by the liver, primarily through cytochrome P450 enzymes CYP2B6 and CYP3A4. At standard therapeutic doses, clinically significant hepatotoxicity has not been reported. However:

• Patients receiving long-term, frequent ketamine should have periodic liver function monitoring
• Patients with pre-existing liver disease may require dose adjustments
• Some case reports of elevated liver enzymes have been noted in patients receiving very frequent or high-dose ketamine, though these typically normalize when treatment is adjusted

Special Population Considerations

Older Adults

Older adults may require dose adjustments due to age-related changes in drug metabolism, body composition, and cardiovascular function. Lower starting doses and more gradual titration are often appropriate. Cardiovascular monitoring may need to be more intensive, and the risk of falls during the recovery period should be addressed.

Adolescents

The use of ketamine in adolescents for psychiatric conditions is an area of active investigation. The developing brain may respond differently to NMDA receptor modulation, and long-term effects on neurodevelopment are not fully established. Treatment in this population should be undertaken only by experienced clinicians with appropriate informed consent and careful monitoring.

Patients with Trauma Histories

Patients with significant trauma histories may be more sensitive to the dissociative effects of ketamine. While dissociation can be therapeutically productive in a supportive setting, it can also be distressing or triggering for some trauma survivors. Careful preparation, lower starting doses, and the availability of a trained therapist during treatment are important considerations.

Monitoring and Safety Protocols

Pre-Treatment Assessment

A thorough pre-treatment evaluation should include:

1. Comprehensive psychiatric history — Diagnosis, previous treatments, medication history, hospitalization history, suicide risk assessment
2. Medical history — Cardiovascular health, liver function, kidney function, endocrine disorders, neurological conditions
3. Substance use history — Past and current use of alcohol, recreational drugs, and prescription medications with abuse potential
4. Medication review — Complete list of current medications and supplements, with attention to potential interactions
5. Baseline vital signs — Blood pressure, heart rate, oxygen saturation
6. Laboratory work (when indicated) — Liver function tests, kidney function tests, thyroid panel, pregnancy test
7. Cardiovascular evaluation — ECG or cardiology referral when clinically indicated
8. Informed consent — Detailed discussion of risks, benefits, alternatives, and expectations

During-Treatment Monitoring

Standard monitoring during each ketamine session includes:

• Blood pressure at baseline, during treatment (every 10-15 minutes for IV; at specified intervals for other routes), and post-treatment
• Heart rate and rhythm
• Pulse oximetry
• Level of consciousness assessment
• Subjective side effect assessment
• Documentation of any adverse events

Post-Treatment Protocol

After each session, patients should:

• Remain in the clinical setting until acute effects have resolved and vital signs are stable
• Be assessed for steady gait and orientation before discharge
• Have a responsible adult available to provide transportation
• Receive clear instructions to avoid driving and operating machinery for at least 12-24 hours
• Know how to contact the clinical team if they experience concerning symptoms after leaving

Ongoing Monitoring

Patients receiving ongoing ketamine therapy should have regular follow-up that includes:

• Assessment of treatment response using standardized measures
• Monitoring for signs of tolerance (needing higher doses for the same effect)
• Screening for urinary symptoms at regular intervals
• Periodic liver function tests (frequency based on treatment intensity)
• Assessment for signs of psychological dependence
• Regular review of the treatment plan to ensure ongoing appropriateness
• Coordination with other treating clinicians

Comparing Safety to Alternative Treatments

Contextualizing ketamine's safety requires comparison to the alternatives faced by patients with treatment-resistant conditions:

Versus Conventional Antidepressants

SSRIs and SNRIs are generally well-tolerated but carry their own risks: sexual dysfunction (affecting 30-70% of patients), weight gain, emotional blunting, gastrointestinal effects, discontinuation syndrome, and the FDA black-box warning about increased suicidality in young adults during the initial treatment period. Importantly, these medications must be taken daily for years and require weeks to take effect, during which time patients remain symptomatic.

Versus Electroconvulsive Therapy (ECT)

ECT is highly effective for severe, treatment-resistant depression but requires general anesthesia, can cause anterograde and retrograde memory impairment (sometimes lasting months), and carries the risks inherent in repeated anesthesia. Cognitive side effects of ECT are generally more pronounced and longer-lasting than those of ketamine therapy.

Versus Untreated Depression

Perhaps the most important comparison is between the risks of ketamine therapy and the risks of continued untreated or inadequately treated depression, which include persistent suffering, functional impairment, job loss, relationship deterioration, physical health consequences, and elevated suicide risk. For patients who have failed multiple conventional treatments, the risk-benefit calculation often favors a trial of ketamine therapy.

Safety in At-Home Settings

The growing availability of at-home ketamine therapy (primarily oral and sublingual formulations prescribed through telehealth providers) raises specific safety considerations:

Essential Safeguards for At-Home Use

• Sitter requirement — A responsible adult should be present during treatment sessions
• Safe environment — Treatment should take place in a comfortable, familiar setting free from fall hazards
• No driving — Transportation plans should be arranged in advance for the remainder of the treatment day
• Communication plan — Patients should have a way to contact their provider or an emergency service if needed
• Medication security — Ketamine should be stored securely to prevent access by children, other household members, or visitors
• Symptom tracking — Regular completion of validated symptom measures (PHQ-9, GAD-7) to assess treatment response
• Regular check-ins — Scheduled telehealth or in-person appointments with the prescribing clinician

When At-Home Use May Not Be Appropriate

At-home ketamine may not be suitable for:

• Patients with active suicidal ideation requiring intensive monitoring
• Patients with a history of substance abuse involving ketamine or dissociatives
• Patients with significant cardiovascular risk requiring blood pressure monitoring
• Patients living alone without access to a reliable sitter
• Patients who have had adverse reactions to ketamine in clinical settings

Regulatory Safeguards

FDA Oversight

The FDA has taken active steps to address ketamine safety in the psychiatric context:

• REMS program for Spravato — Esketamine nasal spray can only be administered in certified healthcare settings with mandatory two-hour monitoring, addressing concerns about misuse and ensuring appropriate oversight
• Compounding oversight — The FDA has issued guidance on compounding pharmacy practices related to ketamine
• Adverse event monitoring — The FDA MedWatch system collects reports of adverse events associated with ketamine use

State Regulations

Many states have implemented or are developing specific regulations for ketamine therapy clinics, addressing issues such as:

• Provider qualifications and training requirements
• Required monitoring protocols
• Documentation and record-keeping standards
• Prescribing limitations for at-home use
• Telehealth prescribing requirements

References

• Short, B., et al. "Side-effects associated with ketamine use in depression: a systematic review." Lancet Psychiatry, 2018. — Comprehensive systematic review of ketamine side effects in psychiatric use.
• Acevedo-Diaz, E.E., et al. "Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression." Journal of Affective Disorders, 2020. — Detailed analysis of acute side effects from controlled clinical trials.
• Niesters, M., et al. "Ketamine for chronic pain: risks and benefits." British Journal of Clinical Pharmacology, 2014. — Review of safety considerations specific to ketamine use in pain management.
• National Institute on Drug Abuse. "Hallucinogens and Dissociative Drugs Research Report." — NIDA report on the pharmacology and risks of dissociative drugs including ketamine.
• World Health Organization. "Ketamine: Expert Peer Review on Critical Review Report." — WHO assessment of ketamine's safety profile and scheduling considerations.